The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil
compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing
following 20 weeks of treatment with omecamtiv mecarbil or placebo
United States: Food and Drug Administration Canada: Health Canada France: National Agency for
the Safety of Medicine and Health Products Germany: Federal Institute for Drugs and Medical
Devices Hungary: National Institute of Pharmacy and Nutrition Italy: Italian Medicines Agency
Netherlands: Medicines Evaluation Board Poland: Chief Pharmaceutical Inspectorate Sweden:
Medical Products Agency
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.